
    
      Through screening (D-30 ~ D-1) prior to the first dose of the investigational product, a
      total of 16 subjects (Group 1: 8 subjects, Group 2: 8 subjects) who were eligible for the
      inclusion criteria and exclusion criteria were enrolled. This clinical study has a
      randomized, open, single dose, 2-sequence, 2-period cross-over design and TEW-7197 50 mg x 4
      tablets were administered as a single dose in the same individual for 2 periods after fasting
      or a high fat diet, and each period was repeated with an interval of at least 1 week of
      wash-out. Pharmacokinetics and safety were evaluated in all subjects according to the planned
      schedule
    
  